Objectives： Ocular effects of Mas-receptor ligands were studied in an experimental rat glaucoma. Elevated IOP （intraocular pressure） was induced unilaterally by laser photocoagulation of the episcleral and limbal v...Objectives： Ocular effects of Mas-receptor ligands were studied in an experimental rat glaucoma. Elevated IOP （intraocular pressure） was induced unilaterally by laser photocoagulation of the episcleral and limbal veins in anesthetized rats. A Mas-receptor agonist （Ang （1-7）） and an antagonist （A779） were administered intravitreally in the glaucomatous eye. lOP was measured by a rebound tonometer. Effects of the treatment on RGCL （retinal ganglion cell layer） were determined stereologically and on the axons of optic nerve by a modified Gallyas silver-staining method. Key findings： Mean IOP during the 14 days follow-up in the solvent treated glaucoma eyes （n = 18） was 28.7 -4- 1.9 mmHg vs. the fellow eyes 11.0 4- 0.3 mmHg. A significant axon damage was detected in the glaucomatous eyes vs. the fellow normotensive eye. The Mas-receptor ligands did not influence high IOP resulted by laser treatment, Despite of the ineffectiveness on lOP, Ang （1-7） protected RGCL cells as determined by stereology （P = 0.016）. No significant effects in Gallyas silver-staining were found. Summary： Intravitreally administered Ang （1-7） showed a significant protective effect against neuronal damage. The present and our previous studies suggest that stimulation of Mas-receptor may have therapeutic potential to treat glaucoma.展开更多
文摘Objectives： Ocular effects of Mas-receptor ligands were studied in an experimental rat glaucoma. Elevated IOP （intraocular pressure） was induced unilaterally by laser photocoagulation of the episcleral and limbal veins in anesthetized rats. A Mas-receptor agonist （Ang （1-7）） and an antagonist （A779） were administered intravitreally in the glaucomatous eye. lOP was measured by a rebound tonometer. Effects of the treatment on RGCL （retinal ganglion cell layer） were determined stereologically and on the axons of optic nerve by a modified Gallyas silver-staining method. Key findings： Mean IOP during the 14 days follow-up in the solvent treated glaucoma eyes （n = 18） was 28.7 -4- 1.9 mmHg vs. the fellow eyes 11.0 4- 0.3 mmHg. A significant axon damage was detected in the glaucomatous eyes vs. the fellow normotensive eye. The Mas-receptor ligands did not influence high IOP resulted by laser treatment, Despite of the ineffectiveness on lOP, Ang （1-7） protected RGCL cells as determined by stereology （P = 0.016）. No significant effects in Gallyas silver-staining were found. Summary： Intravitreally administered Ang （1-7） showed a significant protective effect against neuronal damage. The present and our previous studies suggest that stimulation of Mas-receptor may have therapeutic potential to treat glaucoma.
